

Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting

NCT06712563

Status RECRUITING
Sponsor AstraZeneca
Enrollment 2,000 participants

Key Eligibility Criteria

Inclusion (3)

- Patients with moderate to severe COPD and initiating BGF treatment according to the local prescribing guidance and as per their treating physician's recommendation
- Enrolled in on-going single-arm studies
- Provided consent for secondary use of data

Exclusion (1)

- Did not provide consent for secondary use of data

Locations (7 total)

Research Site, Mississauga, Canada
Research Site, Hamburg, Germany
Research Site, Athens, Greece
... and 4 more locations